1. Home
  2. CREV vs PTIX Comparison

CREV vs PTIX Comparison

Compare CREV & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carbon Revolution Public Limited

CREV

Carbon Revolution Public Limited

HOLD

Current Price

$2.53

Market Cap

3.1M

Sector

N/A

ML Signal

HOLD

Logo Protagenic Therapeutics Inc.

PTIX

Protagenic Therapeutics Inc.

HOLD

Current Price

$1.33

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CREV
PTIX
Founded
2007
1994
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
3.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
CREV
PTIX
Price
$2.53
$1.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
141.7K
101.8K
Earning Date
01-30-2026
11-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$47,677,475.00
N/A
Revenue This Year
$40.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
86.77
N/A
52 Week Low
$1.48
$1.12
52 Week High
$9.45
$14.28

Technical Indicators

Market Signals
Indicator
CREV
PTIX
Relative Strength Index (RSI) 56.65 35.46
Support Level $1.57 $1.12
Resistance Level $1.77 $1.68
Average True Range (ATR) 0.30 0.13
MACD 0.12 -0.00
Stochastic Oscillator 69.96 35.38

Price Performance

Historical Comparison
CREV
PTIX

About CREV Carbon Revolution Public Limited

Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: